Male BALB/c mice were purchased from SLC Inc. (Kotoh-cho, Japan). BALB/c mice were intraperitoneally injected with 100 mg/kg of TAA for 8 weeks, twice a week to induce hepatic fibrosis. The mice were acclimatized for one week prior to experiment and were housed in groups of 3–5 at a temperature of 21 ± 2 °C and 50 ± 5% humidity with a 12 h light/dark cycle.
Seven or eight-week-old ICR mice were purchased from OrientBio Inc. (Siheung, Korea) for the pharmacokinetic study. Mice had free access to food and water. On the experiment day, the mice were fasted for 16 h before oral administration of auranofin or aurocyanide. The animal handlings and experimental procedures were approved by IACUC (Institutional Animal Care and Use Committee, SNU-190924-6 and DGMIF-19071401-00).
Seven or eight-week-old ICR mice were purchased from OrientBio Inc. (Siheung, Korea) for the pharmacokinetic study. Mice had free access to food and water. On the experiment day, the mice were fasted for 16 h before oral administration of auranofin or aurocyanide. The animal handlings and experimental procedures were approved by IACUC (Institutional Animal Care and Use Committee, SNU-190924-6 and DGMIF-19071401-00).
